Lipid Luminations cover art

All Episodes

Lipid Luminations — 174 episodes

#
Title
1

Treating Erectile Dysfunction: Key Cardiovascular Considerations

2

Pharmacometabolomics to Predict Statin Response: Ready for Prime Time?

3

Triglyceride-Lowering Therapies: Addressing Gaps in the Guidelines

4

PCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects

5

Canadian Perspectives on Managing Lipid Disorders in Children

6

Pathogenesis and Management of Non-Alcoholic Fatty Liver Disease

7

Lipid-Lowering Drug Interactions in Cardiovascular Agents

8

Selecting the Right Contraception for the Dyslipidemic Woman

9

Lipidologists Confronting the Obesity Epidemic: Perspectives from NLA President Joyce Ross

10

Big Data in Lipids: Refining Cardiovascular Risk Profiles Nationwide

11

Cardiovascular Risk Reduction in the Elderly: Best Lipid Strategies

12

What's the Deal with Saturated Fat and Cardiovascular Disease Risk?

13

Lipidology's Advances and Growing Pains: Technologies, Drug Trials, and Guidelines

14

The Lipidology Essentials: Making of a Specialty's Annual Summary

15

Recognition and Management of Mental Illness for the Non-Psychiatric Clinician

16

The Life and Times of LDL Cholesterol

17

Clinical Decisions on Cardiovascular Disease: Are Risks or Causes Your Guide?

18

Pathways Toward Better Lipid Medication Adherence

19

Special Populations in Patient-Centered Management of Dyslipidemia

20

Updated NLA Recommendations for African American Patients

21

Dyslipidemia in The Elderly: How Old is "Too Old" to Treat?

22

Dyslipidemia in Children and Adolescents

23

Guidelines for Diagnosis and Management of Dyslipidemia in Patients with HIV

24

Million Hearts Initiative with Dr. Janet Wright, Executive Director

25

Dyslipidemia During Pregnancy: The Risks for Two Patients

26

Statin Intolerance: Keys to Patient Counseling and Guidance

27

Roles of Non-HDL Cholesterol in Risk Assessment and Treatment

28

Keys to the Latest NLA Recommendations for Dyslipidemia Treatments

29

Management of the Patient With Triglycerides 200-499 mg/dl.

30

What is the Safety of Statins in Patients with Diabetes?

31

A Synopsis of the ACC/AHA Risk Assessment and Cholesterol Guidelines

32

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia

33

New Insights on Statin Therapy for Older Patients

34

HPS-2 THRIVE Data and Results

35

Health Information Technology's Impact on Adherence to Lipid Therapy

36

Cardiometabolic Consequences of Sitting Time

37

Generics and Manufacturing: What Prescribers Need to Know

38

Genetic Testing for Familial Hypercholesterolemia

39

Research Updates in Familial Hypercholesterolemia

40

Research Updates on Postprandial Dyslipidemia Treatment

41

Lipid Biomarker Updates: When to Move Beyond the Standard Profile

42

What is HoFH: Detection and Management of the Homozygous Familial Hypercholesterolemia (HoFH) Patient

43

Adiposity, Obesity, and Dyslipidemia

44

Researching Oxidized High-Density Lipoprotein in Obese Adolescents

45

Underrecognition of Diabetes in Cardiology Practice

46

An Avocado a Day: Does It Keep Heart Disease Away?

47

The Impact of Inflammation on HDL Activity

48

Changing Nutritional Needs Throughout the Lifetime

49

Managing CVD in Women During Childbearing Years

50

Obesity, Diabetes and the Metabolic Syndrome

51

Broken Hearts or Broken Bones?

52

Non-pharmacologic Approaches to the Metabolic Syndrome and Diabetes

53

Evolving Treatments: A Review of What’s in the Pipeline

54

Fish Oils: Are They Still Cardioprotective?

55

Treatment Options for Polycystic Ovarian Syndrome (PCOS)

56

Controversy Surrounding the NHLBI Pediatric Guidelines

57

Statin Safety Considerations

58

Emerging LDL Therapies

59

Emerging HDL Therapies: What’s Next on the Clinical Research Horizon

60

Understanding Why Patients Discontinue Statin Therapy

61

Statin Therapy and Diabetes Incidence

62

Lipids and Hormone Therapy

63

Diet Controversies in Lipid Lowering & Cardiovascular Disease Prevention

64

Biomarkers and Lipidology

65

Diagnosis, Prevalence, and Screening of Familial Hypercholesterolemia

66

Fat, Exercise and Cholesterol

67

Managing Lipids in the Chronic Kidney Disease Patient

68

Coronary CT Angiography

69

Genetic Testing to Improve Risk Assessment and Guide Therapies in Patients Facing Heart Disease

70

Management Issues in Familial Hypercholesterolemia

71

Familial Hypercholesterolemia: Risk Stratifications in Practice

72

From Experts to Analytics: What Does Evidence-Based Medicine Mean?

73

CIMT Appropriate Use Guidelines

74

Personalizing Dietary Approaches for Cardiovascular Health

75

LDL Apheresis

76

Imaging Guidelines for Screening CV Risk

77

Fundamentals of Fatty Acids

78

It's Relative: Screening and Treating Familial Hypercholesterolemia

79

Caring for Un- and Under-Insured Patients on Lipid Therapy

80

Current Inquiries in Lipidology: The NLA's Role in the Field

81

Predictive Value of Lipid Biomarkers and Inflammatory Markers

82

The Importance of Omega-3 Fatty Acids

83

Metabolic Syndrome in African Americans: Risk Adjustments & Treatments

84

Atherosclerosis and Cardiovascular Risk Factors in Children

85

Cardiometabolic Risk Reduction in Native Americans

86

The Process of Developing Clinical Guidelines

87

Updates on the ACCORD Trial From the 2010 National Lipid Association Meeting

88

Lipid Management and Systemic Approaches to Patient Care

89

Heart Disease in the United States: Past, Present, and Future Trends

90

Behavioral Strategies for Managing Weight

91

Exercise as Medicine

92

Using HDL in the Clinical Setting

93

Particle Number Testing in the Prevention of Atherosclerosis

94

Strategies to Help Reduce Diseases Associated with Lifestyle

95

Reevaluating Heart Protective vs Destructive Dietary Fats

96

Dietary Fats and Cardiovascular Disease

97

Pediatric Metabolic Syndrome

98

Trends in Stratifying Those With Cardiometabolic Risk

99

Finding Weight Loss Success in a Team-Based Approach

100

Keys to Weight Loss: Specific Nutrients or Just Calories?

101

Lipid Lowering: The End or the Means to Better CV Results?

102

Pursuing Ever More Accurate Cardiovascular Risk Projections

103

Keys to Reversing Pediatric Non-Alcoholic Fatty Liver Disease

104

Eating for Cardiovascular Health

105

A Critical View of JUPITER

106

Hormone Replacement Therapy and Heart Disease

107

NHANES Database Reveals Skyrocketing Triglyceride Levels

108

Carotid Ultrasound Scans for Assessing Cardiovascular Risk

109

Lowering Lipids Through Therapeutic Lifestyle Change

110

Good and Bad Dietary Fats Explained

111

Year in Review: Key Lipid Clinical Trials of 2008

112

JUPITER Study Shows Statins Help Even If Cholesterol Is Normal

113

Using Calcium Scoring for Cardiovascular Risk Prediction

114

Smoking Cessation Strategies for the 21st Century

115

Results of ADVANCE Diabetes Trial

116

The Importance of Non-HDL Cholesterol Testing

117

Cholesterol Management in Children

118

Analysis of the Interheart Study

119

High-Tech Cardiovascular Risk Assessment

120

Do Celebrity Heart Attacks Influence Public Health?

121

Connecting the Dots: Sleep Apnea and Heart Disease

122

Lifestyle Factors to Aid in Lowering Cholesterol

123

The ERA JUMP Study: Reevaluating the Omega-3 Index

124

Could Statins Protect Against Cognitive Decline?

125

Lipid-Lowering Effects of Thyroid Hormone

126

Looking Beyond LDL to Reduce Cardiovascular Events

127

Metabolic Syndrome in Children and Adolescents

128

Managing Insulin-Resistant Patients With Multiple Risk Factors

129

The Latest Targets of Lipid Therapy

130

Does ApoB Trump Non-HDL Measurements?

131

Polycystic Ovary Disease

132

LDL Apheresis

133

Advanced Cholesterol Testing

134

CVD Risk in Special Female Populations

135

The COURAGE Trial: Unpopular to Some, Embraced by Many

136

Impacting Atherosclerosis

137

The COURAGE Trial's Impact on Clinical Practice

138

CVD Risk Factors and Cognitive Impairment

139

Emerging Biomarkers and New Drugs

140

Misconceptions in Coronary Risk & Lipid Medicine

141

Advanced Coronary Risk Assessment Insights

142

CVD Risk Prediction

143

Atherosclerosis Imaging

144

Managing Statin Intolerant Patients

145

The ENHANCE Study

146

Accreditation Council for Clinical Lipidology

147

Diets, Lipids and Heart Disease

148

Managing Metabolic Syndrome

149

In and Around HDL

150

COURAGE Trial - Purpose and Design

151

COURAGE Trial in Hindsight

152

Who was John Gofman?

153

Oh Oh Omega 3!

154

Midwest Lipid Association Conference Series II

155

Midwest Lipid Association Conference Series I

156

The Lowdown on Lipid Lowering

157

Obesity: Identification, Evaluation and Treatment

158

Pediatric Obesity

159

Lipid Issues in the HIV Patient

160

Therapeutic Lifestyle Changes and Lipidology

161

Lipids and Other Markers

162

The Role of the Lipid Clinic & Cardiometabolic Risk

163

What About Subfractions?

164

Non-Statin Safety

165

Statin Safety

166

Diabetic Dyslipidemia

167

Combination Lipid Therapy... What Works?

168

Lipid Issues in Primary Care

169

Pediatric Dyslipidemia

170

OTC Supplement Discussion

171

Menopause and Lipidology

172

Cardiovascular Disease in Women

173

The ABCs of Preventing Heart Disease

174

Becoming a Full Time Lipidologist